Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
(E/Z)-GO289 is a strong and incredibly specific CK2 inhibitor that controls the proliferation of cancer cells as well as circadian cycles. (E/Z)-GO289 has an IC50 of 13 μM against PIM2, which is >1000 times greater than that of CK2[1]. Caki-2, A498 and 769-P cells are strongly inhibited by (E/Z)-GO289 (3-9 μM; 2 days) [1]. Cancer cell proliferation and clock protein phosphorylation are both regulated by (E/Z)-GO289 [1].
|
---|---|
References |
Molecular Formula |
C17H15BRN4O2S
|
---|---|
Molecular Weight |
419.295601129532
|
Exact Mass |
418.01
|
Elemental Analysis |
C, 48.70; H, 3.61; Br, 19.06; N, 13.36; O, 7.63; S, 7.65
|
CAS # |
694522-87-7
|
PubChem CID |
135401714
|
Appearance |
White to off-white solid powder
|
LogP |
4
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
6
|
Rotatable Bond Count |
5
|
Heavy Atom Count |
25
|
Complexity |
452
|
Defined Atom Stereocenter Count |
0
|
SMILES |
COC1=C(C=C(C(=C1)/C=N/N2C(=NN=C2SC)C3=CC=CC=C3)Br)O
|
InChi Key |
DARDDBZKGVEVKB-VXLYETTFSA-N
|
InChi Code |
InChI=1S/C17H15BrN4O2S/c1-24-15-8-12(13(18)9-14(15)23)10-19-22-16(20-21-17(22)25-2)11-6-4-3-5-7-11/h3-10,23H,1-2H3/b19-10+
|
Chemical Name |
5-bromo-2-methoxy-4-[(E)-(3-methylsulfanyl-5-phenyl-1,2,4-triazol-4-yl)iminomethyl]phenol
|
Synonyms |
GO289; GO 289; GO-289
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 16.67 mg/mL (39.76 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 1.67 mg/mL (3.98 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3849 mL | 11.9246 mL | 23.8493 mL | |
5 mM | 0.4770 mL | 2.3849 mL | 4.7699 mL | |
10 mM | 0.2385 mL | 1.1925 mL | 2.3849 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.